vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and OXFORD INDUSTRIES INC (OXM). Click either name above to swap in a different company.

OXFORD INDUSTRIES INC is the larger business by last-quarter revenue ($307.3M vs $156.4M, roughly 2.0× BIOCRYST PHARMACEUTICALS INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs -0.2%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs -3.0%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Oxford Industries, Inc. is a publicly traded clothing company in the United States that specializes in high-end clothing and apparel. The company carries many major labels, including Tommy Bahama, Lilly Pulitzer, Johnny Was and Southern Tide.

BCRX vs OXM — Head-to-Head

Bigger by revenue
OXM
OXM
2.0× larger
OXM
$307.3M
$156.4M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+7.7% gap
BCRX
7.5%
-0.2%
OXM
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
-3.0%
OXM

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
BCRX
BCRX
OXM
OXM
Revenue
$156.4M
$307.3M
Net Profit
$-63.7M
Gross Margin
60.3%
Operating Margin
13.6%
-27.7%
Net Margin
-20.7%
Revenue YoY
7.5%
-0.2%
Net Profit YoY
-1517.6%
EPS (diluted)
$0.00
$-4.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
OXM
OXM
Q1 26
$156.4M
Q4 25
$406.6M
$307.3M
Q3 25
$159.4M
$403.1M
Q2 25
$163.4M
$392.9M
Q1 25
$145.5M
Q4 24
$131.5M
$308.0M
Q3 24
$117.1M
$419.9M
Q2 24
$109.3M
$398.2M
Net Profit
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
$245.8M
$-63.7M
Q3 25
$12.9M
$16.7M
Q2 25
$5.1M
$26.2M
Q1 25
$32.0K
Q4 24
$-26.8M
$-3.9M
Q3 24
$-14.0M
$40.6M
Q2 24
$-12.7M
$38.4M
Gross Margin
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
97.7%
60.3%
Q3 25
98.6%
61.4%
Q2 25
98.3%
64.2%
Q1 25
96.9%
Q4 24
95.4%
63.1%
Q3 24
97.3%
63.1%
Q2 24
98.4%
64.9%
Operating Margin
BCRX
BCRX
OXM
OXM
Q1 26
13.6%
Q4 25
64.0%
-27.7%
Q3 25
18.6%
6.3%
Q2 25
18.2%
9.2%
Q1 25
14.6%
Q4 24
-3.4%
-2.0%
Q3 24
6.6%
12.5%
Q2 24
8.0%
13.2%
Net Margin
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
60.5%
-20.7%
Q3 25
8.1%
4.1%
Q2 25
3.1%
6.7%
Q1 25
0.0%
Q4 24
-20.4%
-1.3%
Q3 24
-12.0%
9.7%
Q2 24
-11.6%
9.6%
EPS (diluted)
BCRX
BCRX
OXM
OXM
Q1 26
$0.00
Q4 25
$1.13
$-4.28
Q3 25
$0.06
$1.12
Q2 25
$0.02
$1.70
Q1 25
$0.00
Q4 24
$-0.13
$-0.25
Q3 24
$-0.07
$2.57
Q2 24
$-0.06
$2.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
OXM
OXM
Cash + ST InvestmentsLiquidity on hand
$259.0M
$8.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$528.0M
Total Assets
$465.1M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
OXM
OXM
Q1 26
$259.0M
Q4 25
$274.7M
$8.0M
Q3 25
$212.9M
$6.9M
Q2 25
$260.0M
$8.2M
Q1 25
$295.1M
Q4 24
$320.9M
$7.0M
Q3 24
$96.8M
$18.4M
Q2 24
$78.4M
$7.7M
Stockholders' Equity
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
$-119.2M
$528.0M
Q3 25
$-387.9M
$597.1M
Q2 25
$-421.6M
$592.4M
Q1 25
$-451.9M
Q4 24
$-475.9M
$612.2M
Q3 24
$-468.6M
$621.6M
Q2 24
$-475.6M
$592.9M
Total Assets
BCRX
BCRX
OXM
OXM
Q1 26
$465.1M
Q4 25
$514.2M
$1.3B
Q3 25
$446.4M
$1.3B
Q2 25
$457.2M
$1.3B
Q1 25
$480.0M
Q4 24
$490.4M
$1.2B
Q3 24
$491.3M
$1.2B
Q2 24
$472.4M
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
OXM
OXM
Operating Cash FlowLast quarter
$-9.1M
Free Cash FlowOCF − Capex
$-47.9M
FCF MarginFCF / Revenue
-15.6%
Capex IntensityCapex / Revenue
12.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-79.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
$292.0M
$-9.1M
Q3 25
$41.6M
$83.5M
Q2 25
$41.3M
$-3.9M
Q1 25
$-27.5M
Q4 24
$-5.2M
$-18.2M
Q3 24
$8.2M
$88.8M
Q2 24
$-1.4M
$32.9M
Free Cash Flow
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
$291.2M
$-47.9M
Q3 25
$40.3M
$52.3M
Q2 25
$41.1M
$-27.4M
Q1 25
$-27.7M
Q4 24
$-5.9M
$-56.9M
Q3 24
$8.2M
$47.2M
Q2 24
$-1.5M
$21.0M
FCF Margin
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
71.6%
-15.6%
Q3 25
25.3%
13.0%
Q2 25
25.2%
-7.0%
Q1 25
-19.0%
Q4 24
-4.5%
-18.5%
Q3 24
7.0%
11.2%
Q2 24
-1.4%
5.3%
Capex Intensity
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
0.2%
12.6%
Q3 25
0.8%
7.7%
Q2 25
0.1%
6.0%
Q1 25
0.1%
Q4 24
0.5%
12.6%
Q3 24
0.1%
9.9%
Q2 24
0.1%
3.0%
Cash Conversion
BCRX
BCRX
OXM
OXM
Q1 26
Q4 25
1.19×
Q3 25
3.23×
5.00×
Q2 25
8.12×
-0.15×
Q1 25
-859.91×
Q4 24
Q3 24
2.19×
Q2 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

OXM
OXM

Sales Channel Retail$162.9M53%
Sales Channel Wholesale$61.3M20%
Johnny Was$45.4M15%
Sales Channel Food And Beverage$29.3M10%
Other Foreign Countries$9.0M3%

Related Comparisons